Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Guided Therapeutics (GTHP) Accumulated Depreciation & Amortization (2019 - 2020)

Guided Therapeutics' Accumulated Depreciation & Amortization history spans 2 years, with the latest figure at $1.7 million for Q4 2020.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 27.04% to $1.7 million in Q4 2020 year-over-year; TTM through Dec 2020 was $1.7 million, a 27.04% decrease, with the full-year FY2020 number at $1.7 million, down 27.04% from a year prior.
  • Accumulated Depreciation & Amortization hit $1.7 million in Q4 2020 for Guided Therapeutics, down from $2.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for GTHP hit a ceiling of $2.4 million in Q4 2019 and a floor of $1.7 million in Q4 2020.